TAZVERIK Trademark

Trademark Overview

On Thursday, August 3, 2017, a trademark application was filed for TAZVERIK with the United States Patent and Trademark Office. The USPTO has given the TAZVERIK trademark a serial number of 87554273. The federal status of this trademark filing is REGISTERED as of Tuesday, June 16, 2020. This trademark is owned by Epizyme, Inc.. The TAZVERIK trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical products for the treatment of cancer; pharmaceutical products, namely, EZH2 inhibitory drugs
tazverik

General Information

Serial Number87554273
Word MarkTAZVERIK
Filing DateThursday, August 3, 2017
Status700 - REGISTERED
Status DateTuesday, June 16, 2020
Registration Number6080490
Registration DateTuesday, June 16, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 12, 2017

Trademark Statements

Goods and Servicespharmaceutical products for the treatment of cancer; pharmaceutical products, namely, EZH2 inhibitory drugs

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 8, 2017
Primary Code005
First Use Anywhere DateThursday, January 30, 2020
First Use In Commerce DateThursday, January 30, 2020

Trademark Owner History

Party NameEpizyme, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02319
Party NameEpizyme, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02319
Party NameEpizyme, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02319

Trademark Events

Event DateEvent Description
Tuesday, February 6, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, August 7, 2017NEW APPLICATION ENTERED
Tuesday, August 8, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 6, 2017ASSIGNED TO EXAMINER
Monday, November 6, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 22, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 12, 2017PUBLISHED FOR OPPOSITION
Tuesday, December 12, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Saturday, January 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 12, 2019SOU TEAS EXTENSION RECEIVED
Wednesday, June 12, 2019SOU EXTENSION 3 FILED
Wednesday, June 12, 2019SOU EXTENSION 3 GRANTED
Friday, June 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 14, 2018SOU TEAS EXTENSION RECEIVED
Thursday, June 14, 2018SOU EXTENSION 1 FILED
Thursday, June 14, 2018SOU EXTENSION 1 GRANTED
Saturday, June 16, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 15, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, January 15, 2019SOU EXTENSION 2 FILED
Tuesday, January 15, 2019SOU EXTENSION 2 GRANTED
Monday, January 27, 2020SOU TEAS EXTENSION RECEIVED
Monday, January 27, 2020SOU EXTENSION 4 FILED
Monday, January 27, 2020SOU EXTENSION 4 GRANTED
Tuesday, April 14, 2020TEAS STATEMENT OF USE RECEIVED
Tuesday, April 14, 2020USE AMENDMENT FILED
Wednesday, January 29, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 29, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, April 29, 2020STATEMENT OF USE PROCESSING COMPLETE
Wednesday, May 13, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, May 14, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 16, 2020REGISTERED-PRINCIPAL REGISTER
Monday, June 16, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, October 19, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

Related Keywords

tazverik pharmaceutical products inhibitory drugs cancer treatment namely